Pancreatic Cancer Research

ResearcherSwansea UniversityActive in the last 2 years

Bilal A. Al-Sarireh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5974-187X; OpenAlex author ID A5000491757, A5013362957. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
126
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: 6 papers · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 19

  1. Elevated Protein Tyrosine Phosphatase Kappa Expression Is Associated With Disease Progression and Poor Prognosis of Pancreatic Cancer. Co-author DOI 10.21873/cdp.10560↗
  2. Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospectiv… Co-author DOI 10.1016/j.hpb.2024.11.015↗
  3. Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control … Co-author DOI 10.1136/bmjopen-2024-094505↗
  4. Venous Resection During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma-A Multicentre Propensity Score Matching Analysis of the Recurrence After Whi… Co-author DOI 10.3390/cancers17071223↗
  5. Implication of Capillary Morphogenesis Gene 2 (CMG2) in the Disease Progression and Peritoneal Metastasis of Pancreatic Cancer. Co-author DOI 10.3390/cancers16162893↗
  6. Frontline clinical diagnosis-FTIR on pancreatic cancer. Co-author DOI 10.1002/cam4.6346↗
  7. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  8. The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study. Co-author DOI 10.1038/s41416-023-02220-2↗
  9. Oncological outcomes after pancreatoduodenectomy for pancreatic ductal adenocarcinoma in octogenarians: case-control study. Co-author DOI 10.1093/bjsopen/zrad053↗
  10. Measuring blood cell DNA damage using the PIG-A mutation and CBMN assay in pancreatic cancer patients: a pilot study. Co-author DOI 10.1093/mutage/gead006↗
  11. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  12. The Impact of a Centralised Pancreatic Cancer Service: a Case Study of Wales, UK. Last author DOI 10.1007/s11605-020-04612-8↗
  13. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  14. Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. Co-author DOI 10.1016/j.hpb.2021.03.003↗
  15. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  16. Reduced kinase D‑interacting substrate of 220 kDa (Kidins220) in pancreatic cancer promotes EGFR/ERK signalling and disease progression. Co-author DOI 10.3892/ijo.2021.5214↗
  17. A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection. Last author DOI 10.1016/j.hpb.2017.12.009↗
  18. Psoriasin promotes invasion, aggregation and survival of pancreatic cancer cells; association with disease progression. Co-author DOI 10.3892/ijo.2017.3953↗
  19. Pancreatic cancer tissue banks: where are we heading? Co-author DOI 10.2217/fon-2016-0243↗

Closest collaborators

The 25 strongest of 126 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chunyi Hao · 4 shared papers, 2017–2026 · strength 0.69
  2. Keith John Roberts · 5 shared papers, 2021–2025 · strength 0.68
  3. Ziqian Fang · 2 shared papers, 2024–2026 · strength 0.52
  4. Duncan R.C. Spalding · 3 shared papers, 2021–2025 · strength 0.41
  5. Adam Enver Frampton · 3 shared papers, 2021–2025 · strength 0.41
  6. Gareth Jenkins · 2 shared papers, 2022–2023 · strength 0.40
  7. Ricky Harminder Bhogal · 3 shared papers, 2021–2025 · strength 0.39
  8. Lin Ye · 3 shared papers, 2017–2024 · strength 0.36
  9. Wen G. Jiang · 3 shared papers, 2017–2024 · strength 0.36
  10. Lin Ye · 1 shared paper, 2026 · strength 0.33
  11. Zaed Z. R. Hamady · 2 shared papers, 2025 · strength 0.33
  12. Thilo Hackert · 3 shared papers, 2021–2023 · strength 0.31
  13. Hemant Mahendrakumar Kocher · 3 shared papers, 2016–2025 · strength 0.30
  14. Christopher Michael Halloran · 2 shared papers, 2023–2025 · strength 0.29
  15. Nicholas George Mowbray · 2 shared papers, 2018–2022 · strength 0.28
  16. Elizabeth Pando Rau · 2 shared papers, 2023–2025 · strength 0.27
  17. Giuseppe Fusai · 2 shared papers, 2023 · strength 0.26
  18. Samir Pathak · 2 shared papers, 2021–2025 · strength 0.25
  19. Dhanny Gomez · 2 shared papers, 2021–2025 · strength 0.25
  20. Mohammad Abu Hilal · 3 shared papers, 2016–2023 · strength 0.25
  21. Somaiah Aroori · 2 shared papers, 2021–2025 · strength 0.24
  22. Edward Duckworth · 1 shared paper, 2023 · strength 0.24
  23. Debdulal Roy · 1 shared paper, 2023 · strength 0.24
  24. Lucy Nichols · 1 shared paper, 2023 · strength 0.22
  25. Brian Ritchie Davidson · 2 shared papers, 2016–2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.